z-logo
open-access-imgOpen Access
Prevalence and clinical outcomes of nontuberculous mycobacteria in a Brazilian cystic fibrosis reference center
Author(s) -
T.B. Aiello,
Carlos Emílio Levy,
Tânia Regina Zaccariotto,
Ilma Aparecida Paschoal,
Mônica Corso Pereira,
Marcos Tadeu Nolasco da Silva,
José Dirceu Ribeiro,
Antônio Fernando Ribeiro,
Adyléia Aparecida Dalbo Contrera Toro,
Renan Marrichi Mauch
Publication year - 2018
Publication title -
pathogens and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.983
H-Index - 105
ISSN - 2049-632X
DOI - 10.1093/femspd/fty051
Subject(s) - nontuberculous mycobacteria , cystic fibrosis , medicine , epidemiology , isolation (microbiology) , respiratory system , tuberculosis , pathology , mycobacterium , microbiology and biotechnology , biology
Nontuberculous mycobacteria (NTM) have been well established as an opportunistic pathogenic bacterial group for cystic fibrosis (CF) patients, with a prevalence ranging from 3% to 23% worldwide. A myriad of factors can bias the prevalence rate in different CF centers, especially misdiagnosis as systematic screening for NTM are still lacking in a number of centers. Here, we evaluated the presence and clinical outcomes of NTM isolation in microbiological respiratory cultures from CF patients attending a Brazilian reference center after setting up a systematic diagnostic protocol. Of 117 patients with respiratory samples cultured for NTM research, we found seven patients (6%) with at least one positive result for NTM [four males (57.1%), median age = 21 years (9-58)]. These cases are reported one-by-one. Median FEV1 was 40%, all patients showed signs of lung deterioration, with a median number of pulmonary exacerbations of three per patient/year. However, the impact of NTM isolation remains unclear in our center as all patients were coinfected with other CF respiratory pathogens. Our NTM prevalence assimilates to the lowest levels reported in literature, which is possibly influenced by the routinely applied Bacille Calmette-Guérin vaccine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom